Adelaide, South Australia wants to let the secret out, and be known as hub for medical devices, pharmaceuticals, biotechnology, and digital health. It boasts world-class research institutions, such as the University of Adelaide and SAHMRI, fostering innovation and collaboration. The city’s supportive government policies provide incentives, grants, and streamlined regulations for businesses. Adelaide’s skilled workforce, renowned for its expertise in health sciences, offers a talent pool to drive industry growth. Additionally, the city’s strategic location, advanced infrastructure, and strong healthcare ecosystem make it an ideal base for development, manufacturing, and market access, attracting companies in these sectors.
Australian Health Journal spoke to Jo Close, heading the Adelaide arm of MTPConnect about the opportunity its building through its role as the industry growth centre, to help increase commercialisation and collaboration across the sector, optimise the regulatory environment, improving workforce skills and access to markets globally.
One of the companies showing world leading MedTech capabilities arising from Adelaide is Additive Surgical, the first company in Australia to manufacture 3D Printed Titanium novel spinal implant technologies. Its mission is to manufacture the highest quality medical technology in Australia that positively impact the lives of people globally.
Australian Health Journal met with Co-founder and CEO Gibran Maher.
Maher states, “Additive Surgical is committed to supporting Australian innovation and works closely with the Australian clinicians, hospitals, research institutions and universities to innovate and manufacture locally.”
Maher points out the ability to compete is made possible through supportive collaboration with government, research and other enterprises seeking to learn from each other. But to truely compete in international markets, Australia’s needs to further strengthen its sovereign capability.
Currently Australia imports more than 80% of its medical devices. Large multinational companies have very strong market share in Australia and the profits from these companies are largely returned to their international shareholders.
Additive Surgical is committed to manufacturing in Australia, developing intellectual property in Australia and supporting Australian innovation and commercialisation.
You Might also like
-
Updated handbook on chronic kidney disease management in primary care
Kidney Health Australia’s latest kidney disease guide for primary care practitioners is expected to be pivotal in slowing down the rates of kidney failure, which have doubled in the past 20 years and if left unchecked will grow by a further 42% by 2030, according to the health charity.
With specific reference to new kidney treatments and culturally safe kidney care for First Nations Australians, the 5th edition of Chronic Kidney Disease (CKD) Management in Primary Care handbook, known as the ‘kidney bible’, is a significant step-up in enabling earlier diagnosis of kidney disease for GPs and other front-line healthcare professionals.
-
HEALTH CARE BRIEF: Myopia progression in children
Myopia progression in children – Incidence rates, prevalence, risks, symptoms and treatment options
-
Family biz succeeds in vaccine approval & distribution
It’s been 10 years since Jenny and Karl Herz started in business. Over the past 10 years they’ve launched Biointelect and Biocelect businesses to help secure approval and distribution for new medicines into Australia.
In this Australian Health Journal interview, Jenny and Karl talk about the journey the husband and wife team took to get the Novavax COVID-19 vaccine (Nuvaxovid) approved and distributed in Australia. The journey didn’t just include talented and diverse skilled staff but also their children working in both organisations.